FDA approves Enspryng for thyroid eye disease, given by injection

The Food and Drug Administration approved Enspryng for thyroid eye disease on 15 October, adding a second condition to the drug's label and giving the field its first interleukin-6 receptor blocker for the disorder [s1][s2]. Enspryng is satralizumab, made by Genentech; it was already approved for neuromyelitis optica spectrum disorder, and is given by subcutaneous injection rather than intravenous infusion [s1].

Thyroid eye disease, or TED, is an autoimmune inflammation of the tissues behind the eye, usually accompanying the overactive thyroid of Graves' disease. In its active phase it can push the eyes forward, redden and swell the surrounding tissue, and pull the eye muscles out of alignment, causing double vision; in severe cases it threatens sight. The new indication is broad on one axis — it covers TED "regardless of TED activity or duration" in adults — which means it is not limited to the active, early window that has defined much of the existing treatment landscape [s1].

How it is given

Dosing for TED is based on body weight, and differs from the drug's neurology schedule [s1]. Patients weighing 40 to 100 kg receive 120 mg and those above 100 kg receive 180 mg, as loading doses at Weeks 0, 2 and 4, then maintenance every four weeks from Week 8 [s1]. Safety and effectiveness have not been established in TED patients under 40 kg [s1].

Before the first dose, the label requires screening for hepatitis B and tuberculosis and a check of liver transaminases; active hepatitis B and active or untreated latent tuberculosis are contraindications [s1]. That reflects the drug's mechanism: blocking interleukin-6 signalling damps an inflammatory pathway the body also uses to contain infection.

What the trials showed

The approval rests on two identically designed, randomised, double-masked, placebo-controlled Phase 3 trials, Study 3 (NCT05987423) and Study 4 (NCT06106828) [s1]. Together they enrolled 258 patients, of whom 255 received at least one dose and 92% completed through Week 24; most had active, moderate-to-severe disease, with about a quarter inactive [s1]. Patients who had already had surgery or a biologic for TED were excluded [s1].

The primary endpoint was the proptosis responder rate at Week 24 in the active-disease group — the share of patients whose eye protrusion fell by at least 2 mm without worsening in the other eye [s1]. Here the two trials diverged. Study 4 was clearly positive: 52.9% of patients on Enspryng responded against 23.4% on placebo, a difference of 28.9 percentage points (95% CI 11.5 to 46.2, p<0.01) [s1]. Study 3 pointed the same way but missed significance: 49.0% versus 31.2%, a difference of 17.9 points whose confidence interval crossed zero (−1.6 to 37.3, p=0.07) [s1].

That split — two identical trials, one hit and one miss on the headline measure — is the central caveat a reader should carry. The supporting results were more consistent. In Study 4's overall population, including inactive disease, 46.9% responded versus 22.2% on placebo, and among patients with double vision at baseline, 60.7% improved by at least one grade against 25.8% [s1]. Mean proptosis in the study eye fell 1.97 mm on the drug versus 0.96 mm on placebo in the active group of Study 4 [s1].

Safety

Infection is the dominant theme. The label instructs clinicians to delay dosing during any active infection and to avoid live or live-attenuated vaccines during treatment [s1]. Liver enzymes must be monitored, as satralizumab can raise ALT and AST [s1]. In the TED trials, the most common adverse reactions, each at 5% or more, were upper respiratory tract infection and an increase in ALT [s1].

For patients, the approval offers a subcutaneous alternative in a condition whose only drug-specific options have been limited. The honest summary is that satralizumab reduced eye-bulging and inflammation, with one of two pivotal trials meeting its primary endpoint and the other falling just short, and that its place against infusion-based therapy will be worked out in practice.

Red flags for anyone starting it: fever, cough, or other signs of infection warrant contacting the care team before the next dose, and new abdominal pain, dark urine or yellowing of the skin or eyes should prompt liver-enzyme testing.

This article describes an FDA approval and its labelling and is not medical advice. Decisions about treating thyroid eye disease belong with an ophthalmologist and endocrinologist who know the case.